Zidovudine (AZT) and stavudine (d4T) primarily treat HIV infection, though their roles have diminished with the advent of more potent antiretroviral therapies. AZT remains a cornerstone of antiretroviral regimens for pregnant women to prevent mother-to-child transmission. Its use is guided by specific guidelines and considerations for maternal and fetal safety.
Zidovudine’s Role in HIV Treatment
Zidovudine’s mechanism involves inhibiting reverse transcriptase, slowing viral replication. Clinical trials demonstrated significant improvements in survival and CD4 cell counts for patients with HIV. However, its use is now often limited to situations where other antiretrovirals are unsuitable due to cost or patient tolerance, or in specific treatment combinations, such as prophylaxis against opportunistic infections.
Stavudine’s Limited Application
Stavudine’s efficacy is comparable to Zidovudine in some instances but carries higher risks of peripheral neuropathy and pancreatitis. Consequently, its use significantly decreased after the introduction of newer, better-tolerated drugs. Clinicians rarely prescribe stavudine due to these risks, preferring safer alternatives.
Note: Both Zidovudine and stavudine demonstrate varying efficacy depending on the specific HIV strain and patient factors. Individualized treatment plans are paramount, guided by updated clinical guidelines and expert consultation. Always consult a healthcare professional for HIV treatment decisions.
